Wallace Rheumatic Study Center — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$27,148	5
2024	Research	$237	1
2023	Research	$144	2
2022	Research	$475	2
2021	Research	$134,026	37
2020	Research	$12,921	10
2019	Research	$56,123	5

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $93,902 17 payments
Ucb SA $66,790 24 payments
GlaxoSmithKline, LLC. $27,148 5 payments
AstraZeneca UK Limited $21,722 3 payments
Pfizer Inc. $20,477 3 payments
EMD Serono, Inc. $575 8 payments
Novartis Pharmaceuticals Corporation $237 1 payment
Amgen Inc. $224 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus $89,499 14 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $38,371 21 payments
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Followed By An Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus. $28,166 1 payment
A Phase 4, Multicenter, Prospective, Open-Label Study Describing the E $27,148 5 payments
Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS) $21,722 3 payments
A Phase 1 Randomized Multicenter Doubleblind Sponsor Open Placebocontrolled Single and Multiple Doseescalation Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Pf06835375 in Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis $20,477 3 payments
A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT) $4,403 3 payments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE) $575 8 payments
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus $252 2 payments
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-Of-Care Therapy in Patients With Active Lupus $237 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.